ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacologic Relapse Prevention for Alcoholic Smokers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000457
Recruitment Status : Completed
First Posted : November 3, 1999
Last Update Posted : October 21, 2013
Sponsor:
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information provided by:
Mayo Clinic

November 2, 1999
November 3, 1999
October 21, 2013
June 1998
April 2002   (Final data collection date for primary outcome measure)
Will bupropion reduce relapse to smoking compared to placebo [ Time Frame: 52 weeks and 76 weeks ]
Determine if long-term use of bupropion will reduce the rate of relapse to smoking compared to placebo in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy projected to achieve 100% replacement.
Not Provided
Complete list of historical versions of study NCT00000457 on ClinicalTrials.gov Archive Site
Does matching the dose of nicotine patches to nicotine levels help increase smoking abstinence [ Time Frame: 8 weeks ]
Determine the week 8 smoking cessation rate in recovering alcoholics provided a nicotine patch dose projected to achieve 100% replacement.
Not Provided
Not Provided
Not Provided
 
Pharmacologic Relapse Prevention for Alcoholic Smokers
Pharmacologic Relapse Prevention for Alcoholic Smokers
This study will compare the long-term use of bupropion (Wellbutrin) and placebo for reducing the rate of smoking relapse in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy. The study will also determine the cessation rate in the 8th week of treatment among recovering alcoholics using a nicotine patch. The patch dose is projected to serve as a 100-percent replacement.
The purpose of this trial was to recruit 292 recovering alcoholic smokers (abstinent from alcohol for a minimum of 1 year), who want to stop smoking and provide them with 100% nicotine replacement. The 100% nicotine replacement will be undertaken using a nicotine patch. By measuring their nicotine levels at study entry we can determine the patch dosing needed. The patch dosing will vary from 22 mg to 44 mg. Those who are able to achieve tobacco abstinence by week 8 will enter a relapse prevention phase for the remaining 44 weeks. In this phase, they will be randomized to active or placebo bupropion (300 mg/day). After 44 weeks of the relapse prevention trial (at week 52 of study participation), they will enter a post medication follow up for 6 months.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Alcoholism
  • Smoking
  • Drug: bupropion (Wellbutrin)

    1 pill in the am of 150 mg of Bupropion

    1 pill (150 mg) in the AM and one in the PM for a total of 300 mg per day for subsequent 44 weeks.

    Other Names:
    • bupropion
    • zyban
    • wellbutrin
  • Drug: Placebo
    placebo pill to match (look alike) the 150 mg pill of the bupropion given in the am for 3 days and then two pills (one in the morning and one at night) for the subsequent 44 mg.
    Other Names:
    • bupropion
    • zyban
    • wellbutrin
  • Placebo Comparator: Placebo
    Subjects who achieved smoking abstinence and give a bupropion-placebo (sugar) pill for 44 weeks in order to prevent relapse to smoking. Brief Behavioral Counseling is also given during this time.
    Intervention: Drug: Placebo
  • Active Comparator: Bupropion
    Subjects who achieved smoking abstinence and give bupropion (300 mg/day) for 44 weeks in order to prevent relapse to smoking. Brief Behavioral Counseling is also given during this time.
    Intervention: Drug: bupropion (Wellbutrin)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
195
292
August 2007
April 2002   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • History of alcohol dependence and at least one year of abstinence from alcohol intake.
  • Has a history of smoking 20 or more cigarettes per day for the prior year.
  • Can read and write English.
  • Stated ability to fully participate in the study and keep all scheduled appointments.
  • Has provided written informed consent.
  • General good health.

Exclusion Criteria:

  • Recent history (within three months) of a clinically significant myocardial infarction, unstable angina pectoris, serious cardiac arrhythmia or any other medical condition which the physician investigator deems incompatible with study participation.
  • Current major depression. A past history of major depression will not be an exclusionary criteria.
  • Current or previous use of bupropion (Wellbutrin).
  • Active non- nicotine drug dependence.
  • Past or current history of bipolar disorder, pain disorder or psychosis, schizophrenia, or other major psychiatric disorders.
  • Current medically indicated use of psychiatric drugs.
  • Females who are pregnant, lactating, or likely to become pregnant during the first year which includes the nicotine patch and bupropion (Wellbutrin) phase.
  • History of severe skin allergies or evidence of severe chronic skin disorders.
  • Current use of nicotine containing medication or tobacco products other than cigarettes.
  • Current use (within 30 days of initiation of patch therapy) of the following medications for smoking cessation: clonidine, buspirone, or doxepin.
  • A predisposition to seizures.
  • A history of or current diagnosis of anorexia nervosa or bulimia.
  • Medical disorder that would interfere with the absorption, metabolism, or excretion of bupropion (Wellbutrin).
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00000457
972-95
R01AA011219 ( U.S. NIH Grant/Contract )
No
Not Provided
Not Provided
Richard D. Hurt, MD, Mayo Clinic
Mayo Clinic
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Principal Investigator: Richard D Hurt, MD Mayo Clinic
Mayo Clinic
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP